The U.S. Food and Drug Administration (FDA) recently updated safety warnings on Myrbetriq extended-released tablets after reports of angioedema in some users.
Angioedema involves the swelling of tissue beneath the outer skin, and can be fatal if the swelling blocks a person’s upper airway. Myrbetriq patients reported angioedema of the face, lips, tongue, and larynx as early as after the first dose.
Myrbetriq (mirabegron) is used to treat overactive bladders. In addition to angioedema, Myrbetriq extended-release tablets may also lead to Stevens–Johnson Syndrome, a life-threatening condition wherein the top layers of skin separate from the lower layers, exposing the body to infection.
The FDA advises patients taking Myrbetriq to discontinue treatment and seek medical attention if they experience any swelling of the tongue, hypopharynx, or larynx.
Notify your doctor if you have any health concerns about the medications you are taking. Pharmaceutical companies have a responsibility to adequately test their products and report any potential side effects. If you believe a drug you took caused you to develop a condition like angioedema or Stevens–Johnson Syndrome, you should contact the lawyers at Lopez McHugh for a free legal consultation.
